

ASX ANNOUNCEMENT

Update – Progress of Corporate Plan

27 September 2017: Analytica Ltd is pleased to announce the next step in development of the PeriCoach® and AutoStart® Burette with the appointment of a US corporate advisory firm.

"As announced at the AGM in 2015, reiterated at the AGM in 2016 and cost reduction announcement in March 2016, the board implemented a plan for the PeriCoach - build the best in class, prove it works and look for partnering opportunities. With the release of the PeriCoach V3, the 8-week challenge and data collection program, and the appointment of corporate advisors, the company continues to make progress in its commercialisation plan" said Chairman Dr Monsour.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.

